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Abstract  
There is an urgent need to reduce reliance on hypodermic injections for many 
vaccines to increase vaccination safety and coverage. Alternative approaches include 
controlled release formulations, which reduce dosing frequencies, and utilizing alternative 
delivery devices such as microneedles patches (MNPs). This work explores development of 
controlled release microparticles made of poly (lactic-co-glycolic acid) (PLGA) that stably 
encapsulate various antigens though aqueous active self-healing encapsulation (ASE). These 
microparticles are incorporated into rapid-dissolving MNPs for intradermal vaccination.  
PLGA microparticles containing Alhydrogel are loaded with antigens separate from 
microparticle fabrication using ASE. This avoids antigen expsoure to many stressors. The 
microparticles demonstrate bi-phasic release, with initial burst of soluble antigen, followed 
by delayed release of Alhydrogel-complexed antigen over approximately two months in vitro. 
For delivery, the microparticles are incorporated into MNPs designed with pedestals to 
extend functional microneedle length. These microneedles readily penetrate skin and rapidly 
dissolve to deposit microparticles intradermally. Microparticles remain in the tissue for 
extended residence, with MNP-induced micropores resealing readily. In animal models these 
patches generate robust immune responses that are as-good-as or better than conventional 
administration techniques. This lays the framework for a versatile vaccine delivery system 
that could be self-applied with important logistical advantages over hypodermic injections. 
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Introduction 
While vaccines represent our strongest weapons against contagious disease, several 
obstacles still limit their maximum potential. For example, most vaccines require booster 
doses to induce protective levels of immunity. Besides, the large molecular size of vaccine 
antigens often prevents oral administration, and hypodermic injections are necessary to elicit 
the desired immune response. The reliance on repeated hypodermic injections creates many 
logistical challenges, such as difficulties with storage, disposal, and administration via 
healthcare professional. This not only increases costs, but also decreases availability, 
particularly in developing nations. If the full booster schedule is not administered, an 
individual may not develop protective immunity. Furthermore, hypodermic needles are 
designed for intramuscular (i.m.) delivery. However, the muscle has a low level of resident 
antigen-presenting cells (APCs), thus requiring higher doses than would be needed when 
compared to more APC-dense tissue such as the skin1-4  
In an effort to increase the availability of vaccines and improve worldwide 
vaccination coverage, the next generation of vaccines should reduce reliance on hypodermic 
injections. This could be achieved through multiple approaches. One option is developing 
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single-administration vaccines, which may offer protective immunity from a single dose.5 A 
second concept, which could be accomplished separately or in tandem, is to utilize alternative 
delivery devices such as microneedle patches (MNPs) that avoid the logistical hurdles of 
hypodermic needles and are also more patient-friendly.4,6-9 
A promising route to developing safe single-administration vaccines is through 
controlled antigen release.5,10,11 This can be pulsatile to mimic current prime-boost 
paradigms,12,13 or continuous to mimic a naturally developing infection.14,15 In either case, the 
goal is to develop protective immunity via extended/delayed antigen exposure from a single 
administration. A common approach for controlled release is to encapsulate the active 
ingredient in a bio-erodible polymer such as a poly(lactic-co-glycolic acid) (PLGA).16-18  
While this approach has generated commercial success with various small molecules and 
peptides, it has not historically translated well to biomacromolecules such as protein 
antigens.19 This is primarily due to the harsh stresses experienced during fabrication and 
sterilization of the microparticles, which are known to damage sensitive proteins.20-24  
Newer approaches however allow for the separation of microparticle fabrication from the act 
of protein loading, thus allowing stable protein to be encapsulated.24-26 This method, termed 
active self-healing encapsulation (ASE), employs a protein-trapping agent inside the 
microparticles, which draws protein into the microparticles from an aqueous solution at high 
efficiency, followed by a dynamic self-healing process of microparticles’ surface pores that 
trap protein inside the microparticles (Figure 1A).24,26,27 This method is well suited for protein 
antigens, and has great potential for the development of a single-administration controlled 
release vaccine delivery system. 
4 
 
This article is protected by copyright. All rights reserved.
Whereas these PLGA controlled release systems have potential for reducing overall 
dosing requirements, they still rely on hypodermic needles for administration, which are often 
disliked by patients, require serious storage and disposal considerations, and generally must 
be administered by a healthcare professional.1,6,8,28 MNPs are an attractive alternative, as they 
do not suffer from many of the obstacles mentioned above. In brief, MNPs are typically 
patches containing small sharp projections (~100-1000 µm) that penetrate into superficial 
layers of the skin and deliver a therapeutic payload intradermally (i.d.).4,6,7,28,29 Due to their 
small size, the patches cause little or no pain and generally no bleeding.30,31 They also have 
reduced storage/disposal requirements, and may dissolve entirely after application, leaving 
behind no biohazardous sharps waste, which reduces risk of accidental stick or reuse.32 
Furthermore, MNPs are generally preferred by patients over traditional hypodermic injections, 
and can be successfully self-administered without a healthcare professional.8 Lastly, by 
delivering the payload to the skin, they take advantage of the potent intradermal immune 
system, which can generate stronger responses than what is typical of the muscle, or can 
generate equivalent responses from lower doses.1,4,33,34 
Explored here is the combination of controlled protein antigen release from PLGA 
microparticles loaded via ASE with the logistical and immunological benefits of 
administration via microneedles. PLGA microparticles are first fabricated without antigen 
present, containing only the common vaccine adjuvant Alhydrogel, and trehalose as a 
stabilizing and pore-forming excipient. A variety of different vaccine antigens are then 
loaded into the same microparticle formulation using the ASE loading paradigm. These 
microparticles are then incorporated in a microneedle patch, where the controlled antigen 
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release behavior is evaluated in vitro. These patches readily penetrate skin and then rapidly 
dissolve to deliver the microparticles intradermally where they reside to release antigen. This 
system has great potential as a self-applied and versatile controlled release vaccine delivery 
system. 
 
Results and Discussion 
Fabrication and Evaluation of ASE-loaded PLGA Microparticles 
The formulation parameters of the ASE PLGA microparticles were selected to 
produce spherical, porous microparticles within the desired size range (10 – 60 µm) that 
demonstrated self-healing when incubated in solution above the glass-transition temperature 
(Tg).27,35 The Tg of the dry microparticles was 46.5 °C, while after hydration this value 
dropped to 32.6 °C (Supplementary Material). The observed Tg depression of the hydrated 
microparticles is expected because of the well-known plasticization effect of water on 
polymers.36 The microparticles were well formed and highly porous as observed via scanning 
electron microscopy (SEM) (Figure 1B). The hydrated microparticles had a volume-weighted 
mean diameter of 35.0 µm; larger than the limit up to which phagocytic cells can internalize a 
particle.37 Thus, encapsulated antigen will likely be hidden from the immune system until it is 
released from the microparticles as soluble or adjuvant-bound protein. 
The major advantage of the ASE loading strategy is it allows formulation 
optimization of the preformed microspheres in the absence of protein. This reduces the 
amount of potentially expensive protein wasted during pilot formulation studies. Any 
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microparticles larger than the desired size could be excluded from the final product with 
particle sieves without wasting antigen. 
To evaluate the microparticles’ ability to load different antigens, dry and unloaded 
microparticles were co-incubated with various antigen solutions during a loading gamut that 
included 48 h at 42 °C. After this period, the pores on the microparticle surface had partially 
or fully healed (Figure 1B). This serves to close off some diffusion pathways for soluble 
antigen, and slows the inital burst release. While many different loading conditions, including 
varying antigen concentration, volume, or maximum temperature, successfully produced 
antigen-loaded microparticles, it was found using ovalbumin (OVA) as the model antigen 
that 0.5 mL of a 1 mg/mL OVA solution incubated with 20 mg of microparticles for 2 d at 
4 °C, followed by 1 day at room temperature, and 2 d at 42 °C produced the best combination 
of w/w antigen loading and encapsulation efficiency (EE%) for this formulation 
(Supplementary Material). Also, a variety of antigens, both model and clinically relevant, 
were successfully encapsulated into the exact same formulation of microparticles – i.e., 
alterations to the microparticles were not needed to accommodate different antigens. The 
changes in w/w loading generally correlated with the antigens’ affinity for the Alhydrogel 
that was included in the formulation (Table 1).  It should be noted that the time used for self-
healing encapsulation in the above protocol is undesirably long. Means to accelerate the 
loading via the use of plasticizers in the polymer, for example, are currently under 
investigation.  
Alhydrogel is a common vaccine adjuvant currently included in many different 
vaccines.38,39 It was loaded into the microparticles at 3.5% (theoretical w/w). The adjuvant 
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binds to antigens to create colloidal particles, thus extending their residence time and 
increasing phagocytosis.38-40 Here, Alhydrogel also acts as an agent to preferentially 
sequester antigen inside the microparticles. That is, during incubation antigen diffuses into 
the microparticle pores where it binds Alhydrogel to become trapped inside the 
microparticles (i.e., loading) before the surface pores heal under elevated temperature. 
Because Alhydrogel can bind to most proteins at pH above the protein’s pI, it offers a 
versatile system to work with many different antigens without the need to change the 
microparticle formulation. The primary additional consideration is for thermoliable antigens 
– in this case the anthrax antigen rPA and the plague antigen F1-V. In order for these antigens 
to remain stable during the loading conditions, an appropriate stabilizer, such as 20% w/v 
trehalose added to the antigen solution was necessary, as has been previously reported.41 
While the addition of trehalose as an excipient stabilized the antigen, it also interferes with 
loading. When 20% trehalose was added to OVA controls, loading was reduced by 45% (data 
not shown). Thus, future studies focused on formulations with OVA and Hepatitis B surface 
antigen (rHBsAg).  
 
Development of Microneedle Patches Containing ASE Microparticles 
Microparticles were then incorporated into microneedles composed of highly water-
soluble materials (i.e., polyvinyl alcohol (PVA) and sucrose). In this way, the microneedles 
dissolve quickly in the skin (thereby allowing the MNP to be removed from the skin within a 
few minutes), leaving the microparticles deposited as a depot within the skin. MNPs were 
prepared using “standard” microneedles (Figure 2A) and using “pedestal” microneedles that 
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were mounted atop a pedastal to improve microneedle insertion into deformable skin (Figure 
2C). The PVA/sucrose composition was selected as it maximized solid content of the filling 
solution, while also providing an acceptable viscosity. 
Previous work has explored incorporating nanoparticles into microneedles,42-44 but 
incorporation of microparticles into microneedles has received limited attention.29 In this 
study, the microparticles are large and thus remain extracellular during release. Furthermore, 
this is the first time microparticles loaded via the ASE loading technique have been utilized 
in a MNP, which is expected to improve antigen stability.24  
When making standard patches, microparticles could be readily observed in the 
microneedles, with few particles in the backing (Figure 2A and B). The process was also 
easily adapted to include a pedestal design that increased the functional length of the 
microneedles while keeping the microparticles localized to the microneedle portion (Figure 
2C and D).  
The standard and pedestal MN patches contained approximately 244 µg and 208 µg of 
microparticles, respectively (Table 2). The difference was likely due to the extra 
manipulation required of the pedestal patches. Using the model antigen OVA, which loads 
into the microparticles at 1.6% (w/w), this corresponded to a final antigen dose of 4.0 and 3.4 
µg/patch for standard and pedestal patches, respectively (Table 2). Also, each patch is 
expected to contain less than 10 µg of alhydrogel – well below the FDA limit of 0.85 
mg/dose, even if multiple patches were administered. The antigen loading would be expected 
to change when using different antigens. To adjust dosage, several options are possible, such 
as changing the number of microneedles in the array, using multiple patches, or diluting the 
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microparticles with a packing excipient. It may be challenging to incorporate additional 
microparticles in this size range into a microneedle without changing the overall geometry. 
Pedestal-based microneedles are helpful for overcoming the elasticity of the skin and 
ensuring more full penetration/insertion of the microneedles into the tissue. Using a standard 
pyramidal/conical microneedle design, it is common for only 25% of the total microneedle 
volume to be dissolved or deposited in the tissue.45-47 The pedestal design utilized here was 
crafted using 3D-printed master parts that were re-cast using soluble materials. While 3D 
printing lacks the micron-scale percision and accuracy of photolithograpy, presice 
dimensions and smooth surfaces are not generally required of the pedestal part, so 3D 
printing was an effective means of reducing fabrication costs and time. In addition, by 
creating a pedestal patch that is fully soluble, it eliminates considerations for disposal of 
biohazardous waste versus other two-part systems.47,48 While the standard microneedles had a 
height of 600 µm, and the pedestal part was 800 µm tall, the final tip-to-base height of the 
pedestal patches was 1183 ± 6 µm, suggesting roughly 200 µm of overlap between the 
pedestal and the microneedle, as confirmed by confocal imaging (Figure 2D). 
 
In Vitro Controlled Release 
In vitro release was evaluated for both independent microparticles and MNPs 
containing microparticles using both model (OVA) and clinically relevant (rHBsAg) antigens. 
For MNPs, encapsulated microparticles were first liberated from the PVA/sucrose 
microneedle matrix by dissolving and rinsing with cold dI-H2O to avoid interference with the 
antigen signal. Soluble antigen release from MNPs was observed to occur over 2-4 weeks. 
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This included an initial burst release followed by a slight linear phase. After this period, no 
additional soluble antigen was detectable. During this phase, ~ 60% of encapsulated OVA, 
and ~10% of rHBsAg were released (Figure 3A). The difference between the two antigens’ 
release profiles is likely due to differences in their predominant binding mechanism to the 
Alhydrogel inside the microparticles. Antigens can bind Alhydrogel through two dominant 
mechanisms; reversibly through electrostatic interactions, and irreversibly through ligand 
exchange.49,50 OVA binds primarily through electrostatic interactions,49 thus a larger 
percentage is expected to desorb from the Alhydrogel and diffuse out of the microparticles 
during this phase. rHBsAg, however, binds primarily through ligand exchange.51 Thus, a 
lower percentage desorbs and more remains inside the microparticles as a particulate 
complexed to Alhydrogel.49,52 It is noteworthy that in vivo, the dissolution and clearance of 
the PVA/sucrose binding material would be anticipated to take additional time. Thus, the 
early stage of antigen release is expected to occur slower in vivo than under the in vitro test 
described above. 
The stability of the antigen released during this early phase was evaluated by 
comparing antigen concentration as determined by size-exclusion chromatography (SEC) to 
that determined via an ELISA method (Figure 3B). Stability, particularly at the early 
timepoints, was near 100%, with little or no decreases at later timepoints. This suggests the 
combination of the ASE technique along with the presence of stabilizing excipients in the 
microparticles and MNPs successfully stabilized the antigen during the loading, microneedle 
fabrication, and freeze-drying phases. Release from microparticles not incorporated into 
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MNPs was generally similar, but with a slightly larger burst release and higher total percent 
soluble release (Supplementary Material). 
To confirm that the remaining fraction of antigen (antigen that did not desorb from 
Alhydrogel and release from the microparticles as soluble antigen) was still inside the 
microparticles and had not released as a soluble aggregate or degradation product, 
microparticles were subjected to total nitrogen analysis after 35 days of in vitro release (Table 
3). After day 35, the standalone microparticles had released ~70% of encapsulated OVA. 
Since the polymer and other excipients are nitrogen-free, the total nitrogen content can be 
correlated back to protein content. Roughly 27% of encapsulated protein was recovered (97% 
total recovery). This strongly suggests the fraction of antigen that is not released during the 
soluble release phase is remaining inside the microparticles as a ligand-bound particulate 
complexed with Alhydrogel, although protein aggregation could not be ruled out. 
To evaluate the release characteristics of this remaining antigen fraction, a fluorescently-
labeled OVA (fOVA) was encapsulated into microparticles using the ASE technique. Figure 
4A shows the colloidal particles formed by adsorbing fOVA onto Alhydrogel – small 
particulates no more than a few microns in diameter. Figure 4B-F show microparticles loaded 
with fOVA after 1, 2, 3, 4, and 6 weeks of in vitro release (after washing away any soluble 
antigen released). After one and two weeks, the microparticles showed no obvious signs of 
bulk degradation, and the florescent signal was still localized to the microparticles only. After 
3 weeks, however, degradation of the polymer microparticles was apparent both in confocal 
and SEM images (Supplementary Material). As this happened, mass loss of the polymer 
occurred and larger pores began to form. This allowed the Alhydrogel-fOVA complex to 
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escape, which was visible outside the microparticles. This was more apparent at week 4, 
where the complex was now more visible, and heavy microparticle degradation was obvious. 
By week 6, the microparticles were fully degraded and the remaining fraction of Alhydrogel-
complexed antigen was released and available for presentation to the immune system. Again, 
because of the larger size of these microparticles, antigen still encapsulated inside the 
microparticles is hidden from the immune system until release. 
 
Skin Penetration and Microparticle Delivery 
To evaluate skin penetration, excised porcine inner ear tissue was used. Standard and 
pedestal patches were pressed into taut skin with the thumb. Standard patches produced a full 
100 clearly identifiable microchannels, while pedestal patches produced an average of 98 ± 2 
(n=5, ± SEM) microchannels (Figure 5A and B). This suggests the patches possess the 
mechanical integrity necessary to penetrate skin tissue. 
To verify that after the microneedles penetrate skin they dissolve intradermally to 
deliver microparticles, pedestal MNPs were fabricated with microparticles loaded with fOVA. 
The resulting MNPs were applied as above, but the patches were allowed to remain in the 
tissue for 20 mins to dissolve. After removing the patches, the tissue was fluorescently 
imaged to visualize the microparticles (Figure 5C). The fluorescence was localized to the 10 
X 10 grid pattern, strongly suggesting the microneedles dissolve intradermally and release the 
microparticle payload, and the microparticles do not spread out either on the surface of the 
skin or within the tissue. Afterwards, the tissue was frozen and cryosectioned to visualize 
cross-sections of the skin at the application site. Figure 5D shows a representative cross-
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section of the tissue, and confirms that microparticles had been intradermally deposited via 
the MNPs. Together, Figures 5C and D suggest that microparticles are not left on the surface 
of the skin where they would be inactive, but rather are deposited below the stratum corneum, 
mostly in the dermis.  
After removing the partially dissolved patches from the tissue, it was apparent that 
some microparticles had not been deposited and remained on the patch after administration 
(Supplementary Material). The fraction left in the patch could not be determined 
gravimetrically, as the patches picked up a considerable amount of tissue and hair. Rather, a 
GPC method was developed to quantify the mass of polymer left on the patch after 
administration. As shown in Table 2, the standard patches only delivered 25% of the 
microparticles (consistent with previous results, when presented),45,46 while the addition of 
the pedestal improved this significantly, to 55%. In addition to the elasticity of the skin, 
insertion is likely limited by rapid dissolution of the microneedle tip, which could quickly 
become dull after insertion and prevent further tissue penetration. To further improve 
delivery, slower dissolving and materials could be investigated, possibly coupled with more 
advanced microneedle-fabrication methods. 
 
Skin Resealing and In Vivo Microparticle tracking 
A potential concern for advancing MNP technologies is the sub-millimeter pores 
introduced in the skin by application of the patch. If these micropores do not close quickly 
the potential for infection may exist, although prior reserarch suggests this risk is small.53 
While several studies have investigated the kinetics of skin resealing, the existing literature 
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focuses on solid, non-dissolving-type MNPs that do not deposit any material in or otherwise 
occlude the micropores.54-56 Thus, it was necessary to explore the skin resealing kinetics after 
application of the MNPs used here in order to evaluate if the microparticles, or the 
PVA/sucrose microneedle matrix, affected the skin’s ability to close the micropores. To 
evaluate skin resealing, trans-epithelial water loss (TEWL) was measured, as it correlates 
well to the barrier properties of the skin.57  
Four styles of patches were evaluated: A) a non-dissolving MNP of equivalent 
geometry that was made of high Mw poly(lactic acid) (PLA) (fabricated as previously 
reported58) and did not deposit material in the skin, B) the microparticle-loaded dissolving 
pedestal MNPs explored above, C) dissolving pedestal MNPs that contained nanoparticles 
rather than microparticles (median diameter = 7.1 µm),59 and D) a dissolving pedestal MNP 
that did not contain any microparticles (vehicle). 
Immediately after application, TEWL values for all test groups rose significantly 
(Figure 6). The PLA patches generated a higher response than the other groups, likely 
because the stronger, non-dissolving material allowed for the creation of a larger/deeper 
wound not filled with dissolved material or particles. 
Within six hours of application, micropores introduced by the PLA patches had 
largely resealed. This is consistent with previous literature suggesting pores made from solid 
non-dissolving MNPs reseal quickly.54 Micropores from vehicle patches and from patches 
containing smaller nanoparticles mostly resealed by the end of the first day, whereas those 
from the microparticle patches resealed between the second and third day. These data suggest 
that material deposited in the skin by dissolving microneedles acts as an occlusion and slows 
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the skin resealing process, and that resealing is further slowed by larger particles as compared 
to smaller ones or only soluble material. However, the skin still resealed within a resonable 
timefrime, likely encapsulating the microparticles in the dermal space. Additional studies are 
needed to determine the relationship between skin resealing and possible infection or leakage 
of microparticles out of the skin. 
While penetration and microparticle deposition studies are useful to determine how 
well MNPs deposit their payload when applied, it is also important to determine the behavior 
of the microparticles and antigen in the skin over time. While it is generally understood that 
soluble materials are readily delivered to the circulation and/or lymphatics, the behavior of 
larger biodegradable depots is less well characterized. To evaluate this, microparticles were 
again loaded with fOVA and fabricated into pedestal MNPs. Patches were applied to shaved 
mice which were imaged over time to evaluate the strength and localization of the fluorescent 
signal. Values were compared against i.d. injected microparticles and soluble OVA. 
After administration, the application site was highly visible through fluorescent 
imaging, with individual micropores identifiable (Figure 7). Over the next 3-10 days, the 
application site retained its fluorescence for patches and injected microparticles. After only 
one day, however, the soluble antigen signal was heavily attenuated and was lost entirely by 
day 3. As this retention is longer than the time required to reseal the skin, it suggests that 
microparticles deposited by the MNPs are not quickly pushed out of the skin either by the 
rapid turnover of the epidermal layer,60 or by the general movement of the animals. The 
signal from MNP-deposited microparticles was slightly attenuated compared with injected 
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microparticles, possibly due to some loss from the surface or from the animals cleaning the 
application site, which may have removed additonal microparticles. 
 
Immunizations via ASE Microparticles and Microneedles 
To determine if the microparticles delivered hypodermically or via a MNP stimulate 
an immune response, mice were dosed with microparticles containing OVA or rHBsAg by 
multiple routes of administration. Two MNPs were applied to the shaved dorsal flank, while 
an equivalent delivered dose of antigen-loaded microparticles were hypodermically injected 
either i.d. or i.m. Control groups consisted of equivalent delivered antigen doses of 
Alhydrogel-adsorbed antigen (positive control), soluble antigen, or MNP containing antigen-
free microparticles (negative control/sham). Booster doses were given 21 days after the 
priming immunization. 
On day 42, blood was drawn and analyzed for anti-OVA or anti-rHBsAg total IgG 
serum levels, as well as IgG1 and IgG2c, which are indicators of Th2 and Th1-type 
immunity, respectively.61 For both antigens, all microparticle and/or MNP-dosed groups 
showed high antigen-specific total IgG levels compared with the sham and soluble OVA 
groups, and were as-good-as or better than the conventional vaccine group with Alhydrogel-
adsorbed antigen (Figure 8A and B). Similar trends were observed for IgG1, whereas only 
i.d. and i.m. injected OVA-loaded microparticles elicited weakly significantly elevated IgG2c 
levels (Supplementary Material). Given that Alhydrogel-adsorbed antigens do not frequently 
generate Th1 responses, and coupled with high levels of IL-10 levels produced by 
restimulated splenocytes (Supplementary Material), these data suggest that delivery using 
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microparticles and MNPs are capable of generating robust Th2-type immune responses that 
perform as-well-as or better than conventional vaccination approaches in mice. Furthermore, 
this approach was readily translatable to different antigens without any changes to the 
formulation or fabrication process, as evidenced by high IgG levels for both OVA and 
rHBsAg. 
Blood was also drawn and analyzed on day 20, one day before booster doses). In this 
case, microparticles, but not MNPs, showed significantly higher antigen-specific IgG levels 
compared to controls. The delay of onset for the MNPs is likely the result of a combination of 
factors including: A) additional time required to dissolve and clear the PVA/sucrose binding 
material, B) hydration of the freeze-dried microparticles, and C) a slight delay in controlled 
release kinetics between the microparticles and microneedle patches (Supplementary 
Material). This difference was even more apparent in the rHBsAg groups. At day 20, no 
response was observed in the groups dosed with MN patches, while the Alhydrogel-adsorbed 
group already showed a response. As was shown in Figure 3, the rHBsAg released more 
slowly (less released in the soluble phase), and thus the response takes longer to develop. 
However, research suggests that slower releasing antigens generate stronger final immune 
responses than quick releasing antigen.15 
These results support further scientific development of hypodermic needle-free 
vaccination via ASE microparticle-containing microneedle patches, and that the ASE 
microparticles used in the MNPs may be a useful method for sustained exposure of antigen to 
the immune system. The MNPs produced responses that were generally equivalent to i.d. 
injection of microparticles, but did not rely on a hypodermic needle for injection. This 
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seemingly minor detail actually has enormous consequences for improving vaccination 
coverage for reasons mentioned above, including higher patient acceptability, self-
application, and easier storage/disposal. It is unexpected that i.m. injection of microparticles 
produced equivalent or occasionally stronger responses than i.d./MN administration, as this 
trend is typically reversed in the existing literature. 33,42 
The controlled release potential of these polymer-based delivery systems was also 
apparent. For example, rHBsAg was shown to release more slowly than OVA from the 
microneedles in vitro (Figure 3). Before booster doses, it appeared that Alhydrogel-adsorbed 
rHBsAg was producing a more robust IgG response, whereas after boost the responses were 
nearly equivalent. The faster releasing OVA, on the other hand, generated a response more 
quickly and surpassed the conventional formulation by day 42. This trend may suggest that 
the slower release of antigen could delay the development of the immune response, but may 
also lead to the production of a stronger response once release is complete. This is also true of 
the comparison between the microneedle patches and i.d. microparticles, as the patches were 
shown to release antigen more slowly than free microparticles.  
 
Conclusions 
The vaccine delivery system developed here combines three major components to 
form a new platform that has multiple advantages over traditional vaccine delivery. First, it 
utilizes PLGA microparticles loaded via the active self-healing encapsulation-loading 
paradigm. This system maintains antigen stability by avoiding antigen exposure to the 
protein-damaging stresses present during traditional microparticle fabrication/antigen 
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encapsulation. Also, by utilizing the common vaccine adjuvant, Alhydrogel, as the ASE agent 
that draws antigen into the microparticles, it adds versatility to the system. That is, many 
antigens that bind to Alhydrogel and are or can be made reasonably temperature stable can be 
loaded into the same microparticle batch without necessitating any changes to the formulation. 
Second, the system relies on controlled antigen release via PLGA microparticles.  These are 
capable of performing as-well-as if not better than traditional prime-boost vaccine schedules. 
Removing the need for multiple injections is one of the largest obstacles to improving 
worldwide vaccination coverage, and thus is an important component of the system 
developed here. Lastly, by incorporating the antigen-loaded microparticles into a soluble 
microneedle patch, multiple logistical and scientific advantages become apparent. These 
patches are smaller, can be self-administered, and will dissolve completely to avoid creating 
biohazardous sharps waste. They are also more likely to be preferred by patients, as they 
generate minimal or negligible pain and bleeding and are unlikely to induce needle-phobia. 
Microneedles also utilize the powerful intradermal immune system, which may be more 
advantageous than traditional i.m. delivery. While additional modifications to the system 
could further improve its utility, this work lays a foundation for a self-administered single-
administration vaccine system that is applicable to a variety of vaccines and thus disease 
states.  
 
Materials and Methods 
PLGA Microparticle Fabrication and Loading  
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Antigen-free porous PLGA microparticles were prepared via a water-in-oil-in-water 
(w/o/w) solvent evaporation method adapted from methods previously reported.24 350 mg 
PLGA 50:50 (i.v. = 0.60 dL/g, ester terminated) was dissolved in 1 mL dichloromethane. The 
inner-water phase was prepared by concentrating Alhydrogel (2%, Invivogen) to 6.35% via 
centrifugation and removal of excess solution, then 8% w/v trehalose was added and the 
slurry was mixed. 0.2 mL of the inner-water phase was added to 1 mL of the dissolved 
polymer phase, then homogenized for 1 minute at 17k rpm on a Tempest I.Q.2 Sentry 
Microprocessor to create the primary w/o emulsion. The theoretical alhydrogel loading was 
thus 3.5% (w/w). 2 mL of a 5% (w/v) poly(vinyl alcohol) (PVA) solution was then added to 
the primary emulsion and vortexed for 50 s. Lastly, the resulting w/o/w emulsion was poured 
into 100 mL of a 0.5% (w/v) PVA solution and hardened under rapid stirring for 3 hours. The 
resulting microparticles were passed through a 60-µm and 10-µm sieve in series and washed 
with ddH2O to remove excess PVA. Excess liquid was remove and the microparticles were 
freeze-dried for 48 h. 
Microparticles were loaded with antigens using ASE.24,26 Flocculated antigens (OVA 
& rPA) were resuspended at a stock concentration of 1 mg/mL in 10 mM MOPS buffer, pH 
7.4. F1-V and rHBsAg were first buffer exchanged from PBS to MOPS, then brought to a 1 
mg/mL stock in MOPS. 0.5 mL of 1 mg/mL antigen solution was added to 20 mg 
microparticles, protected from light and rotated for 2 d at 4 °C, 1 d at room temperature, and 
2 d at 42 °C. After incubation the suspension was centrifuged and the supernatant was 
removed and saved for analysis via HPLC/UPLC-SEC and/or ELISA. Microparticles were 
either then used directly to create MNPs, or freeze-dried for independent use. Loading and 
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encapsulation efficiencies (EE%) were determined using the following formulas using the 
lost mass of antigen from the loading solution compared against positive controls. 
 
% w/w loading: 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠  ×  100 % 
 
EE%: 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑏𝑦 𝑚𝑖𝑐𝑟𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛  ×  100 % 
 
Fabrication of Microneedle Patches 
MNP fabrication methods have been described previously and their adaptation to this 
study is summarized here45 The patches were fabricated by casting onto 
polydimethtylsioxane (PDMS) molds to produce MNPs containing a 10 X 10 array of 
pyramidal microneedles (300 µm X 300 µm X 600 µm) with tip-to-tip spacing at 640 µm. 
To make standard MNPs (lacking a pedestal), antigen-loaded microparticles were first 
washed 3X with MOPS, then resuspended in cold ddH2O at an approximate concentration of 
40 mg/mL and kept on ice. 25 µL of the microparticle suspension was pipetted onto the 
surface of the PDMS mold, and the mold was pulled under vacuum for 10 mins at 
approximately 25 in.Hg. Excess suspension was then removed and returned to the stock for 
reuse. The mold was then centrifuged for 10 mins at 3220 rcf at 4 °C. Excess microparticles 
were removed from the surface of the mold via gentle tape-stripping. Approximately 90 µL 
of a 40% PVA + 30% sucrose (w/v) solution was then applied over the molds, and pulled 
under vacuum for 30 mins. The patches were then allowed to dry in a fume hood overnight 
before being demolded and trimmed of excess material around the edges to form a ~1 cm2 
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square patch. The patches were then freeze-dried for >48 h. Patches were stored under 
desiccation at 4 °C until use. 
Plastic pedestal masters were 3D printed with assistance from the University of 
Michigan 3D lab using a ProJet 3500 HD Max printer. The pedestal was prepared based on 
lithography methods previously described.48 It consisted of a 10 X 10 array that could be 
overlaid onto the MNP mold (equivalent center-to-center spacing of 640 µm), made of 
pyramidal trapezoids with a 300 µm wide square base, 800 µm tall, and a 130 µm wide 
square top. After fabrication the mold was cleaned of printing oil, then a PDMS mold was 
cast from the structure. This new mold allowed the pedestal part to be recreated using 
excipients with expected excellent biocompatibility (PVA/sucrose). 
To create pedestal patches, the aforementioned patch process was carried out 
identically through the first centrifugation step. After tape-stripping away excess surface 
microparticles, 25 µL of the PVA/sucrose mixture (as above) was vacuumed onto the mold 
for 10 min while the mold was covered to prevent evaporation and premature hardening of 
the patch. Surface PVA/sucrose was then removed using a razor under a stereomicroscope 
(Nikon Olympus). The PVA/sucrose pedestal part was then manually aligned with the 
microneedle cavities (still in the mold) such that the tip of each pedestal aligned with the tip 
of the microneedle molds. The pedestal was then gently pressed into the mold and was 
allowed to dry in-place in a fume hood overnight. Patches were then demolded and freeze-
dried. Each patch used in this study was visualized on a stereomicroscope to ensure 
microneedle quality. Malformed patches were occasionally formed, but discarded. 
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In vitro release and stability 
For in vitro evaluation of antigen-loaded microparticles, microparticles were 
resuspended in 1 mL PBST (PBS + 0.02% Tween 80). For MNPs, four patches were first 
dissolved in ddH2O and rinsed 5X to remove PVA/sucrose microneedle matrix material, then 
the remaining microparticles were resuspended in 0.25 mL PBST. Release studies were 
carried out at 37 °C while protected from light and shaken at 240 rpm. At each timepoint (1, 
3, 7 days and weekly thereafter), samples were spun-down and the full release media was 
removed for antigen analysis via HPLC/UPLC-SEC and/or ELISA. 
 
Size Exclusion Chromatogaphy of Antigens 
Unless otherwise stated, antigen concentration was determined by size-exclusion 
chromatography (SEC) using either high or ultra performance liquid chromatography 
(HPLC/UPLC). In either case, the mobile phase consisted of PBS, pH 7.4, flowed at 1 
mL/min (HPLC) or 0.4 mL/min (UPLC). Injection volumes were 50 or 10 µL for HPLC and 
UPLC, respectively. All samples were filtered through 0.45 µm filters prior to injection. A 
TSKgel G3000SWxl column was used for HPLC and an Acquity BEH SEC (4.6 X 150 mm) 
column was used for UPLC. UV detection was done at 215 nm. All samples were carried out 
in triplicate or greater, and only monomeric protein content was considered. 
 
Total Nitrogen Analysis 
Total protein content was extrapolated from total nitrogen content using a modified 
automated Dumas technique.62 Microparticle pellets were washed 3X with ddH2O, then 
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freeze-dried. 1 – 4 mg of microparticles were massed into tin pans, which were crimped to 
remove excess air. Samples were run on a Leco TrueSpec® Micro CHN. The instrument was 
first blanked without samples to establish atmospheric baselines. Carbon, hydrogen, and 
nitrogen standards were then set in the anticipated range of nitrogen mass using USP-grade 
EDTA. Lyophilized antigen standards were run to verify the percent nitrogen in the protein 
and set a Protein Factor. Microparticle samples were then dropped into the combustion 
chamber at 1050 °C, which converts all nitrogen to nitrogen gas, which is then quantified by 
a thermal conductivity cell. Protein content was determined by multiplying the nitrogen mass 
by the protein factor after first subtracting the nitrogen mass from negative controls 
(unloaded microparticles). Percent protein could then be determined by dividing protein mass 
by total sample mass. 
 
Confocal Microscopy 
To visualize the distribution of antigen inside the microparticles after encapsulation, 
microparticles were loaded using an Ovalbumin-Alexa Fluor 647 conjugate (fOVA) similar 
to as described above. After washing, the microparticles were resuspended in ddH2O and 
placed on a glass slide with a coverslip and cross-sectional Z-stacked images were taken on a 
Nikon A-1 spectral confocal laser scanning microscope (CLSM) operating with a Cy5 filter 
and NIS Elements viewing and analysis software. 
To evaluate the particulate release fraction, fOVA-loaded microparticles were 
resuspended in PBST and sent to release at 37 °C. At predetermined time points, a sample of 
the suspension was removed and washed with ddH2O before similarly imaging as above via 
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CLSM. Images were compared against Alhydrogel that had similarly been loaded with fOVA 
and washed of unbound antigen. 
 
Microneedle Insertion 
For ex vivo evaluation of mechanical integrity, excised porcine ear tissue was used. 
The shaved inner skin with cartilage attached was separated from the outer skin and 
subcutaneous fat, and pinned taut. MNPs were gently placed tip-down onto the skin, and 
pressed in firmly with the thumb for 10 s. The patch was then removed and Gentian Violet 
(Ricca Chemical Co.) was applied to the application site for one minute before being wiped 
away with an alcohol pad. The application site was then cut away and imaged on a 
stereomicroscope (n = 5 for each patch type). 
To evaluate depth of penetration/microparticle deposition, microparticles loaded with 
OVA-AlexaFluor 488 conjugate were fabricated into MNPs and the experiment was 
performed similar to above, except patches were held on the tissue for 5 minutes with 
pressure, then placed in a 37 °C chamber at 98% humidity for 15 additional minutes to allow 
the microneedless to dissolve. The backing of the patches was gently removed and the 
application site tissue was cut out and embedded in OCT compound, which was subsequently 
dipped in isopentane chilled by surrounding LN2. The samples were then cut into 50 µm 
sections using a Leicia 3050S cryostat onto Superfrost+ microscope slides. Slides were 
thawed and immediately imaged on an Olympus fluorescent stereomicroscope.  
To determine the mass of microparticles delivered upon application of MNPs, male 
nude BALB/c mice were cleared of any light hair using depilatory cream (Nair®) one day in 
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advance of patch application. Mice were anesthetized and placed on a heated pad to maintain 
body temperature. A fold of skin from the dorsal flank was pulled from the body and held 
taut on a cutting board. A MNP was gently pressed into the skin for 5 min. Pressure was then 
removed and the patch was kept on the skin for an additional 15 min. The remaining portion 
of the patch was then removed and placed in a microcentrifuge tube. Four patches were used 
per sample (n=3 samples). The patches were then dissolved in ddH2O and washed 5X, then 
dried in a vacuum oven at 40 °C overnight. To account for residual animal tissue that was 
picked up by the patches, the mass of microparticles remaining in the patches after 
application was determined by Gel Permeation Chromatography (GPC). Briefly, the residual 
microparticles were dissolved in tetrahydrofuran (THF), filtered, and ran on a GPC column 
against standard masses of dissolved microparticles. 
 
In vivo Microparticle Tracking 
The treatment of all experimental animals in these procedures were in accordance 
with University committee on use and care of animals (University of Michigan UCUCA), and 
all NIH guidelines for the care and use of laboratory animals. Pedestal MNPs were made 
loaded with fOVA and applied to male albino C57BL/6J mice as described above. Two 
patches were applied per mouse, to the left anterior and right posterior dorsal flank. At 
predetermined time-points, the whole animal was anesthetized and imaged using a 
PerkinElmer IVIS Spectrum imaging system. Fluorescence data was processed using a 
region-of-interest (ROI) analysis with background subtraction using Living Image 4.5 
software. Other study groups included mice given an i.d. injection to the same locations of an 
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equivalent delivered dose of fOVA-loaded microparticles or soluble fOVA. Mice were kept 
on an alfalfa-free diet to reduce autofluorescence. Depilatory cream was not reapplied during 
the study, but hair was kept trimmed using electric razors (n=4 mice/group, 2 applications per 
mouse). 
 
Skin Resealing 
Transepithelial water loss (TEWL) was measured using a Delfin Technologies VapoMeter 
with DelfWin 4 capture software. Study groups consisted of application of: A) PLA master 
patches (no pedestal), B)ASE microparticle-loaded pedestal patches, C) pedestal patches 
loaded with smaller nano-sized PLGA particles,59 and D) vehicle-only patches (pedestal 
MNPs made of only PVA/sucrose, no microparticles). Three measurements were taken per 
application site, per animal, at each timepoint, and the TEWL chamber was allowed to re-
equilibrate to environmental conditions before each measurement. To measure TEWL, the 
VapoMeter was gently pressed against the application site without manual tension applied to 
the skin. Data is presented as percent increase over an application control using ANOVA 
with Fisher’s LSD. The application control consisted of a flat PVA/sucrose mock patch that 
did not contain any microneedles, but was applied similarly to other groups.  
 
Immunizations 
C57Bl/6 (for OVA groups) or BALB/c (for rHBsAg groups) mice, 5-6 weeks old, 5 
mice/group, were purchased from Jackson Laboratories. The choice of mouse strain was 
reliant on reagents available for the different antigens. One day prior to priming and booster 
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immunization the application site for MN patches or i.d. administered groups was shaved and 
depilatory cream was applied, or just shaved for i.m. administered groups. On day zero mice 
were immunized with either: A) two pedestal MNPs, or equivalent delivered antigen dose 
from, B) i.d. microparticles, C) i.m. microparticles, D) Alhydrogel-adsorbed antigen, or E) 
soluble antigen. A sham group received patches containing microparticles that did not contain 
antigen. Booster doses were given 21 days after the priming dose.  
To evaluate antibody titers, blood was drawn on days 20 and 42 via submandibular 
bleed. Serum was separated using Microvette 500 Zgel serum collection tubes centrifuged for 
5 mins at 10,000 rcf. Serum was stored at -80 °C until analysis. Serum samples were 
analyzed by the University of Michigan Cancer Center Immunology Core for IgG, IgG1, and 
IgG2c via ELISA. Due to reagent availability, antigen-specific IgG1 isotype was used as a 
standard for all IgGs to determine relative concentration. Data was compared using one-way 
ANOVA with Tukey’s post-test via GraphPad Prism® software. 
To evaluate the nature of the cytokine response produced after restimulation of splenic 
lymphocytes, all mice were euthanized on day 42 and spleens were collected under sterile 
conditions. Splenocytes were collected by grinding each spleen through a 70 µm nylon 
strainer. Red blood cells were lysed with ACK lysing buffer and the cells were washed 3X 
with sterile PBS before being resuspended in RPMI 1640 media supplemented with 
glutamine, 10% FBS (10%), 1 U/mL penicillin + 1 µg/mL streptomycin, 55 µM 2-
mercaptoethanol, MEM non-essential amino acids (1%), 1 mM Sodium Pyruvate, and 10 mM 
HEPES. Cells were then plated at 5 x 105 cells/well in a 96-well plate and stimulated with 
media (negative control) or 25 µg/mL whole antigen (OVA or rHBsAg). Positive controls 
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were pooled from each spleen within a group and stimulated with 2 µL/mL PMA/ionomycin 
(cell stimulation cocktail). Cells were incubated for 96 h at 37 °C with 5% CO2 before 
collecting the supernatant and storing at -80 °C. Concentrations of IL2, IL6, IL10, and TNFα 
were analyzed via ELISA through the University of Michigan Cancer Center Immunology 
Core. Stimulated cell supernatants were compared against negative controls using Student’s t-
test. 
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Table 1: Multiple antigens can be loaded into the same microparticle formulation using the ASE technique. 
*20% trehalose added to the loading solution to improve temperature stability. adata from Ref [24], which 
utilized similar microparticle formulations and an identical loading approach. ± SEM.  
 
 
 
 
 
Table 2: Microparticle and antigen mass contained within a single standard or pedestal microneedle patch.  
% MPs delivered represents the percent of microparticles delivered to the tissue after a 20-minute application on 
live mice. ± SEM. 
 
 
 
 
 
Table 3: The fraction of antigen not released from microparticles in vitro during the soluble release phase can be 
accounted for via nitrogen analysis. Approximately 70% of encapsulated OVA was released as soluble antigen 
by day 35 from micropaticles. The remaining samples mass was found to contain approximately 27% of total 
encapsulated OVA, for 97% total recovery. ± SEM 
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Figure 1: A) Schematic of aqueous active self-healing encapsulation (ASE) loading method. 
Porous microparticles containing trehalose-stabilized Alhydrogel are fabricated and freeze-
dried. Microparticles are soaked in an antigen solution, antigen enters the pores and adsorbs 
to Alhydrogel. The solution is then mildly heated, healing the pores and entrapping the 
antigen. Microparticles can then be collected, washed, and utilized. B) SEM images of porous 
ASE microparticles after fabrication and lyophilization (left), and after loading and partial 
self-healing (right). Scale = 20 µm. 
 
Figure 2: Micrographs of microparticle-loaded microneedle patches. A) Standard patch, B) 
fluorescent micrograph of standard patch loaded with fOVA-loaded microparticles, C) 
pedestal patch with sulforhodamine B added to the first PVA/sucrose cast, and D) confocal 
image of individual pedestal microneedle containing microparticles loaded with fOVA. Scale 
= 250 µm. 
 
Figure 3: Microneedle patches encapsulating microparticles demonstrate controlled release of 
stable soluble antigen over approximately one month in vitro. A) Controlled release of soluble 
OVA and rHBsAg from MNPs (solid) and microparticles (for control, dashed). 
B) Immunoreactivity of OVA after release from MN patches, defined as ratio of 
concentration as determined by ELISA to concentration determined via SEC. n=3, ± SEM. 
 
Figure 4: Laser fluorescent confocal images of the microparticles and released Alhydrogel-
fOVA complex during release of Alhydrogel-fOVA complex from ASE microparticles in 
vitro. A) Alhydrogel-fOVA complex without encapsulation. fOVA-loaded ASE 
microparticles after, B) 7 d, C) 14 d, D) 21 d, E) 28 d, and F) 42 d of in vitro release at 37 °C. 
Scale = 100 µm. 
 
Figure 5: Microneedle patches efficiently penetrate the skin and deposit microparticles 
intradermally. Top) Micrographs of excised porcine skin after application and staining of 
penetration sites. A) Standard patch, B) Pedestal patch. Bottom) Fluorescent micrographs of 
tissue after application of pedestal patch containing fOVA-loaded microparticles. C) 
Overhead, D) Cross-sectional. Scale = 1 mm. 
 
Figure 6: Murine skin resealing as measured by TEWL after in vivo application of various 
microneedle patches. Unoccluded micropores made by non-dissolving PLA patches reseal 
rapidly, while micropores with deposited material reseal slower, with larger occlusions taking 
the longest. All values are compaired against a needle-free application control using Fisher’s 
LSD test. **** p <.0001, *** p < .001, ** p <.01, * p < .05. ± SEM. 
 
Figure 7: fOVA-loaded ASE microparticles remain in the skin for several days following 
intradermal administration from microneedles or Mantoux injection (i.d.), with i.d soluble 
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OVA as control, as determined by normalized radiance quantification of fOVA signal at the 
application site. n=8, ±SEM. 
 
Figure 8: ASE microparticles and MNPs generate robust antibody responses. Serum IgG 
levels at day 20 (Left, prime) and day 42 (Right, boost). A) OVA-immunized groups, B) 
rHBsAg-immunized groups. 
Θ Concentrations were determined using an IgG1 standard, and may not be absolute for other 
IgG isotypes.  **** p <.0001, *** p < .001, ** p <.01, * p < .05. n=5, ± SEM 
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